Products

Our pipeline: Delivering first-in-class immunotherapies of activation and regulation

 

Five clinical assets

  • Immuno-Oncology
  • Immuno-Inflammation
Product candidate
Indication (targets)
Research
IND-enabling
Phase 1
Phase 2
Phase 3
NSCLC post-ICI
NSCLC Combo 2L post-ICI
PDAC Combo maintenance
OC Mono or Combo
Solid tumor
UC
KIdney transplant
MSS Endometrial / MSS CRC
Inflammation diseases
CLEC-1 antagonist
Immuno-Oncology
Immuno-Oncology

Significant partnerships with Servier, Boehringer Ingelheim and Veloxis Pharmaceuticals for up to €1.6Bn in milestones (€95 M already received since 2016)

The 3 areas of expertise

Three areas of expertise are being developed within our immunology research platform:

  • T-cell based vaccination
  • Immuno-Oncology (focus on myeloid targets)
  • Auto-Immunity & Inflammation

To receive OSE Immunotherapeutics’ latest news